Grossman Jerrold B 4
4 · ADMA BIOLOGICS, INC. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
ADMA BIOLOGICS (ADMA) Director Jerrold Grossman Receives Award
What Happened
Jerrold B. Grossman, a director of ADMA BioLogics (ADMA), was granted equity awards on February 9, 2026: 10,690 restricted stock units (RSUs) and an additional 17,730 reported as derivative awards. Both grants were recorded at $0.00 per share (award/compensation, transaction code A), so no cash changed hands. These are awards (not open‑market purchases or sales) and are typical form of director compensation rather than a direct investment signal.
Key Details
- Transaction date: February 9, 2026; Form 4 filed February 11, 2026 (timely filing).
- Awards: 10,690 RSUs (award at $0.00) plus 17,730 derivative award units (award at $0.00).
- Vesting: The RSUs vest in two equal installments (six- and 12‑month anniversaries) and will be fully vested on the one‑year anniversary, per the filing (the 10,690 RSUs are noted to fully vest by Feb 9, 2027, subject to continued service).
- Holdings reported (per footnote F2): the reporting person beneficially owns 472,749 common shares and has unvested RSUs including the 10,690 granted Feb 9, 2026 and 5,445 remaining RSUs from a Feb 19, 2025 grant (the 5,445 are scheduled to vest Feb 19, 2026).
- Ownership through entities (per footnotes): some shares are held via Brookwood LLC (Grossman is managing member), the Jerrold Grossman 2019 Irrevocable Trust (he is investment trustee), Genesis Foundation Inc. (he is President), and shares owned by his wife.
- Transaction type: A = Award/Grant (not a purchase, sale, exercise, or gift). No tax‑withholding sale or cashless exercise was reported.
Context
RSU awards are standard compensation for directors and vest over time subject to continued service; they do not represent an immediate sale or purchase of stock. For retail investors, grants are informative about company compensation practices but do not by themselves indicate that insiders are buying (bullish) or selling (bearish).
Insider Transaction Report
- Award
Common Stock
[F1][F2]2026-02-09+10,690→ 488,884 total - Award
Stock Option (Right to Buy)
[F7]2026-02-09+17,730→ 17,730 totalExercise: $16.37Exp: 2036-02-09→ Common Stock (17,730 underlying)
- 22,857(indirect: See footnote)
Common Stock
[F3] - 31,381(indirect: See footnote)
Common Stock
[F4] - 38,294(indirect: See footnote)
Common Stock
[F5] - 175(indirect: See footnote)
Common Stock
[F6]
Footnotes (7)
- [F1]These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.
- [F2]Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 472,749 shares of common stock owned by the reporting person.
- [F3]These shares are owned by Brookwood LLC ("Brookwood"). The Reporting Person is the managing member of Brookwood.
- [F4]These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.
- [F5]These shares are owned by Genesis Foundation Inc. ("Genesis"). The Reporting Person is the President of Genesis.
- [F6]These shares are owned by the Reporting Person's wife.
- [F7]These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.